TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000359365
  • Gene Name:RASSF1A
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:NA
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB01262
  • Drug Name:5-Aza-2-deoxycytidine (5-Aza-CdR)
  • Drug Method:demethylating the promoter to induce the mRNA expression

Disease basic infommation

  • Disease:endometrial cancer
  • Tissue:cell lines ( HEC-1-B)

Other information

  • Title:The Role of 5-Aza-CdR on Methylation of Promoter in RASSF1A Gene in Endometrial Carcinoma
  • Journal:Sichuan Da Xue Xue Bao Yi Xue Ban
  • Published:2015
  • PubMed ID:26121857
  • Abstract:Objective:To explore the effect of demethylating drug 5-Aza-2＇-deoxycytidine (5-Aza-CdR) on methtylation status of the Ras-association domain familylA gene (RASSF1A) in human endometrial carcinoma. Methods:Randomly＇assign the human endometrial carcinoma cell line HEC-1-B into groups and use demethylating drug 5-Aza-CdR of different concentration to treat them. Then Methylation-specific polymerase chain reaction (MSP), real-time PCR, Western blot, TUNEL technology were used to analyze methylation status of RASSF1A promoter CpG islands, RASSF1A mRNA expression, RASSF1A protein expression and apoptosis of HEC-1-B cell. Results:High DNA methylation in RASSF1A gene promoter region, low RASSF1A mRNA level and protein expression and out of control of human endometrial carcinoma cell HEC-1-B apoptosis were observed. 5-Aza-CdR of different concentration could reverse RASSF1A gene＇s methylation status, recover the expression of mRNA and protein, and control the growth of HEC-1-B by inducing apoptosis. Conclusion:Aberrant methylation of RASSF1A in endometrial cancer as a therapeutic target, demethylating agent 5-Aza-CdR could be an effective way of gene therapy.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3